Circulating VEGF levels as a biomarker to clinical benefit to PTC299, the first inhibitor of VEGF synthesis
George, Claude Paul, Luke, Jason John, Winkelman, J., Cao, Yen Thi Kim Hong, Shakes, LaShaina, Donnelly, Kerri, Darby, Charles Harris, Davis, Thomas W., Elfring, Gary L., Schwartz, Gary K.
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article